一个回顾性研究:基于受限立方脊柱模型的乳酸脱酶和割抵抗性前列腺癌之间的关系分析
Ruiying Qiu1, Ke Bu1, Hengqing An2
1Department Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China.
PeerJ
|October 11, 2023
概括
乳酸脱酶 (LDH) 水平与前列腺癌进展到割抵抗性前列腺癌 (CRPC) 相相关. 较高的LDH表明风险增加,这表明LDH是个性化前列腺癌治疗的预后生物标志物.
科学领域:
- 在瘤学瘤学.
- 生物标志物研究 生物标志物研究
背景情况:
- 前列腺癌的进展率以割抵抗性前列腺癌 (CRPC) 在患者之间差异很大.
- 个性化治疗策略取决于准确预测CRPC进展的时间.
- 抗割前列腺癌 (CRPC) 在前列腺癌管理中提出了重大临床挑战.
研究的目的:
- 调查乳酸脱酶 (LDH) 水平与CRPC发生之间的相关性.
- 建立一个理论基础,利用LDH作为前列腺癌患者的预后生物标志物.
- 分析LDH和CRPC风险之间的关系,使用受限立方脊柱模型.
主要方法:
- 从前列腺癌患者的临床和随访数据的回顾性分析,这些患者接受了雄激素缺乏治疗 (ADT).
- 利用COX回归,受限立方脊柱建模和生存分析来评估LDH和CRPC之间的相关性.
- 从2019年10月到2022年8月收集的数据.
主要成果:
- 快速CRPC进展的患者最初表现出较高的TPSA,前列腺体积,LDH和性酸酶水平.
- 多变量COX回归确定了初始的tPSA和LDH水平作为前列腺癌的独立风险因素.
- 限制性立方线分析显示,LDH水平与CRPC风险之间存在线性相关性 (总P<0.05).
结论:
- 乳酸脱酶 (LDH) 与前列腺癌的预后有关.
- LDH 显示了与CRPC发展风险的剂量反应关系.
- 在前列腺癌患者中,LDH作为预测CRPC的潜在预后生物标志物.
相关概念视频
01:21Cancer Survival Analysis
359
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
359
01:20Comparing the Survival Analysis of Two or More Groups
202
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
202